What is the biggest obstacle keeping RNA editing from the clinic?
The most immediate barrier is that the human body's immune system can recognize and attack the very proteins used to perform RNA editing. A 2022 study found that most healthy people already have antibodies and T cells that react to Cas13d, a key editing enzyme from bacteria [4]. This means that simply injecting the editing tool could trigger an inflammatory immune response, potentially destroying the therapy before it works or causing dangerous side effects. This pre-existing immunity is a major reason why even the most advanced RNA editing therapies are still in animal testing, not human trials.
Delivery is another critical bottleneck. Getting the editing machinery to the right cells, especially inside solid tumors, has proven very difficult. A 2026 review on cancer therapy notes that 'limited antitumor activity was observed in solid tumors in preclinical studies due to insufficient delivery of editing tools' [3]. This is a fundamental engineering problem: the editing components are large and fragile, and the body's natural barriers keep them out of many tissues. Until delivery is solved, RNA editing will remain confined to a few accessible organs like the liver.
Which disease is closest to a real RNA editing treatment?
Alpha-1 antitrypsin deficiency (AATD) is the frontrunner. A 2026 study showed that a single RNA-editing drug, SERPINA1-994, corrected 50% of the faulty RNA in the liver cells of mice with the disease [6]. This correction restored normal levels of the protective AAT protein in the blood and, crucially, reduced the toxic buildup of the misfolded protein that causes liver damage [6]. The drug uses a clinically proven delivery technology (GalNAc conjugation) and edits RNA only, not DNA, which lowers the risk of permanent genetic changes [6]. This is the only study here that reports a functional cure in an animal model of a human disease, making AATD the most likely candidate for the first approved RNA editing therapy.
How efficient are these therapies, and is that enough?
Efficiency varies wildly depending on the tool and target, but the best systems can now edit a substantial fraction of cells. For example, a 2024 study using circular RNAs and a Cas12a-based prime editor achieved editing frequencies of up to 40.75% in human cells without any selection [1]. Another approach using circular guide RNAs to recruit the body's own editing enzymes (ADARs) achieved 53% editing of a target RNA in mouse livers [5]. These numbers are impressive, but they also highlight a key trade-off: higher efficiency often comes with more off-target edits. A 2026 review on prostate cancer warns that 'off-target effects and variable editing efficiency' remain 'enduring hurdles' [7]. The field is still learning how to maximize the desired edit while minimizing collateral damage to other RNAs.
The studies agree that circular guide RNAs are a major step forward. Two independent groups found that circularizing the guide RNA boosts editing efficiency by 2- to 40-fold compared to linear guides, without sacrificing specificity [2][5]. This convergence from different labs using different systems (Cas12a, Cas13d, and ADAR-recruiting guides) strongly suggests that circularization is a general strategy that will be used in most future therapies.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2022 to 2026, 4 from 2024 or later, 6 in Q1 journals, collectively cited 315 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 79 papers retrieved from a database of over 500 million.
Sources used in this answer
Prime editing using CRISPR-Cas12a and circular RNAs in human cells
Developed four circular RNA prime editor (CPE) systems using Cas12a, achieving editing frequencies up to 40.75% in human cells without selection, and demonstrating multiplex editing of up to four genes simultaneously.
Engineered circular guide RNAs boost CRISPR/Cas12a- and CRISPR/Cas13d-based DNA and RNA editing
Engineered circular guide RNAs (cgRNAs) that boost Cas12a and Cas13d editing efficiency by 2.1- to 40.2-fold for single genes and 1.7- to 2.1-fold for multiplex editing in cells and in mouse liver, without compromising specificity.
RNA editing: an emerging frontier in cancer therapy – explorations, opportunities, and challenges
Reviews the dual role of RNA editing in cancer (both promoting and suppressing tumors) and identifies key hurdles: off-target effects, variable efficiency, and poor delivery to solid tumors, which limits preclinical antitumor activity.
Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans
Shows that most healthy humans have pre-existing antibodies and T cells reactive to the Cas13d enzyme, which could trigger inflammatory immune responses and complicate clinical use of Cas13d-based therapies.
Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs
Engineered circular ADAR-recruiting guide RNAs (cadRNAs) that achieved 53% editing of a target RNA in mouse livers and 12% correction of a nonsense mutation in a mouse model of Hurler syndrome, with high specificity.
RNA editing for the treatment of alpha-1 antitrypsin deficiency
Developed SERPINA1-994, a GalNAc-conjugated oligonucleotide that corrects 50% of the Z mutation RNA in mouse hepatocytes, restoring normal AAT protein levels, reducing toxic aggregates, and decreasing inflammation in a model of alpha-1 antitrypsin deficiency.
The regulatory mechanism and clinical significance of RNA editing in prostate cancer
Reviews the role of RNA editing in prostate cancer progression and therapy resistance, highlighting ADAR1 and APOBEC3 enzymes as therapeutic targets and noting that off-target effects and variable efficiency remain hurdles.